Bora Pharmaceuticals' Subsidiary Morning Sun Biotech Acquires Health Brand WGN, Marking Another Global Expansion
Bora Pharmaceuticals' subsidiary, Morning Sun Biotech, has acquired the US-based sports nutrition brand Weider Global Nutrition (WGN) for 50 million USD. This acquisition aims to strengthen Bora Pharmaceuticals' global sales strategy and establish it as a leading health food brand group in Taiwan.
📋 Article Processing Timeline
- 📰 Published: May 5, 2026 at 20:24
- 🔍 Collected: May 5, 2026 at 20:31 (7 min after Published)
- 🤖 AI Analyzed: May 5, 2026 at 20:40 (8 min after Collected)
TAIPEI (CNA) – Bora Pharmaceuticals announced today another step forward in its global sales expansion, with its subsidiary Morning Sun Biotech's board of directors approving the 100% acquisition of Weider Global Nutrition (WGN), a sports nutrition brand founded in Arizona, USA. The signing and closing took place on the same day. Bora Pharmaceuticals stated that this transaction holds significant strategic importance for advancing its global sales and commercial layout.
Bora Pharmaceuticals indicated that the deal involves a base consideration of 50 million USD in cash, payable in full at closing. An additional approximately 12 million USD will be paid in equity or cash, tiered according to WGN's profit performance over 12 months post-closing.
Bora Pharmaceuticals noted that the funds required for this acquisition will be financed through a combination of bank loans and private placement. Private placement subscribers include Morning Sun's original shareholder, parent company Bora Pharmaceuticals, WTT Investment (Fubon Group family office), and WGN CEO Richard Allen Blair.
According to a McKinsey & Company survey, approximately 50% of consumers in the US and UK prioritize clinical efficacy when purchasing health supplements, making R&D capabilities a critical competitive threshold for health supplement brands, Bora Pharmaceuticals stated.
Bora Pharmaceuticals has a long history of contract manufacturing over-the-counter (OTC) drugs in North America, possessing capabilities in OTC product development and mass production. WGN is actively building its OTC product line, allowing for complementary resources between the two. Additionally, Morning Sun's proprietary fully enclosed solid-state fermentation technology and manufacturing capabilities, combined with WGN's brand recognition, are expected to further enhance management efficiency.
Market observers anticipate that this transaction will elevate Morning Sun to become one of Taiwan's top three health food brand groups, opening a new phase of growth by leveraging Bora Pharmaceuticals' resource network. (Editor: Huang Kuo-lun) 1150505
Choose to stand with facts, your every sponsorship is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
Text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.
Bora Pharmaceuticals indicated that the deal involves a base consideration of 50 million USD in cash, payable in full at closing. An additional approximately 12 million USD will be paid in equity or cash, tiered according to WGN's profit performance over 12 months post-closing.
Bora Pharmaceuticals noted that the funds required for this acquisition will be financed through a combination of bank loans and private placement. Private placement subscribers include Morning Sun's original shareholder, parent company Bora Pharmaceuticals, WTT Investment (Fubon Group family office), and WGN CEO Richard Allen Blair.
According to a McKinsey & Company survey, approximately 50% of consumers in the US and UK prioritize clinical efficacy when purchasing health supplements, making R&D capabilities a critical competitive threshold for health supplement brands, Bora Pharmaceuticals stated.
Bora Pharmaceuticals has a long history of contract manufacturing over-the-counter (OTC) drugs in North America, possessing capabilities in OTC product development and mass production. WGN is actively building its OTC product line, allowing for complementary resources between the two. Additionally, Morning Sun's proprietary fully enclosed solid-state fermentation technology and manufacturing capabilities, combined with WGN's brand recognition, are expected to further enhance management efficiency.
Market observers anticipate that this transaction will elevate Morning Sun to become one of Taiwan's top three health food brand groups, opening a new phase of growth by leveraging Bora Pharmaceuticals' resource network. (Editor: Huang Kuo-lun) 1150505
Choose to stand with facts, your every sponsorship is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
Text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.